Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 56.98

+1.1%

Nov 5 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (19689)	4/11/2006 3:08:32 AM
From: DewDiligence_on_SI	Read Replies (1) of 52153

Judgement - do they make good decisions? In-licenses are the clearest metric here… I nominate FRX as one of the best (if not the best) in-licensors for their size. Celexa, Lexapro, Namenda, and Benicar were all value-enhancing deals. Willingness to cut a program that is marginal is another good thing to look at.< FRX has done this too, on more than one occasion. The most recent case was Combunox. p.s. Judgment has only one “e”. I couldn’t resist after you pointed out the extra “o” in someone’s “loose” :-)

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next